Merck pulled Vioxx off the market in September. LONDON, England (Reuters) – Britons who believe they suffered after taking Merck & Co.’s painkiller Vioxx plan to sue the drugmaker in the U.S. courts next year, a law firm said on Monday.
Link to original article
Successor to Vioxx faces scrutiny amid heart risks
A panel of government advisers questions the cardiovascular safety of the Merck drug Arcoxia.
Merck report absolves managers on Vioxx
Merck & Co.'s board of directors said Wednesday that a 20-month investigation funded by the pharmaceutical company found that senior management acted responsibly in its development and marketing of its now withdrawn pain reliever Vioxx.
New study links Vioxx, Celebrex, Bextra to increased cardiovascular problems (Star-Telegram)
NEW YORK - A new study has linked pain killers Vioxx, Celebrex and Bextra to increased cardiovascular risk, reinforcing findings of other trials that have already sparked concern over the safety of a popular category of drugs.
Contact:
Copyright © 2005 Vioxx Advisor.com All Rights Reserved